Ranbaxy's Loss Is Dr. Reddy's Gain As Merck Shifts R&D Project For Anti-infectives
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - New Jersey-headquartered pharma giant Merck and Daiichi Sankyo-controlled Ranbaxy have mutually agreed to terminate their five-year discovery research collaboration signed in May 2008. The two allies were to discover and engage in clinical development of new products in the field of anti-infectives, mainly anti-fungal and anti-bacterial drug candidates